# Glutaminase Inhibition and Chemoradiation in Advanced Cervical Cancer

> **NCT05521997** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Washington University School of Medicine** · enrollment: 42 (estimated)

## Conditions studied

- Advanced Cervical Carcinoma
- Cervical Cancer
- Cervix Cancer
- Cancer of the Cervix

## Interventions

- **DRUG:** Telaglenastat
- **RADIATION:** Radiation treatment
- **DRUG:** Cisplatin

## Key facts

- **NCT ID:** NCT05521997
- **Lead sponsor:** Washington University School of Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-07-31
- **Primary completion:** 2032-10-07
- **Final completion:** 2032-10-07
- **Target enrollment:** 42 (ESTIMATED)
- **Last updated:** 2026-03-13

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05521997

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05521997, "Glutaminase Inhibition and Chemoradiation in Advanced Cervical Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05521997. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*